SIBN - SI-BONE Inc Stock Price, Fair Value and News

15.51USD+0.17 (+1.11%)Delayed as of 17 Apr 2024, 02:04 pm ET

Market Summary

USD15.51+0.17

Delayedas of 17 Apr 2024, 02:04 pm

1.11%

SIBN Stock Price

View Fullscreen

SIBN RSI Chart

SIBN Valuation

Market Cap

629.9M

Price/Earnings (Trailing)

-14.54

Price/Sales (Trailing)

4.54

Price/Free Cashflow

-23.76

SIBN Price/Sales (Trailing)

SIBN Profitability

Return on Equity

-25.59%

Return on Assets

-18.81%

Free Cashflow Yield

-4.21%

SIBN Fundamentals

SIBN Revenue

Revenue (TTM)

138.9M

Rev. Growth (Yr)

21.61%

Rev. Growth (Qtr)

14.24%

SIBN Earnings

Earnings (TTM)

-43.3M

Earnings Growth (Yr)

1.72%

Earnings Growth (Qtr)

-9.59%

Breaking Down SIBN Revenue

52 Week Range

15.3629.51

(Low)(High)

Last 7 days

-6.1%

Last 30 days

-4.4%

Last 90 days

-18.4%

Trailing 12 Months

-26.6%

How does SIBN drawdown profile look like?

SIBN Financial Health

Current Ratio

9.01

Debt/Equity

0.21

Debt/Cashflow

-0.52

SIBN Investor Care

Shares Dilution (1Y)

17.38%

Diluted EPS (TTM)

-1.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	116.7M	124.4M	132.0M	138.9M
2022	92.1M	95.5M	99.7M	106.4M
2021	77.0M	85.2M	87.1M	90.2M
2020	69.1M	66.9M	71.1M	73.4M
2019	57.7M	60.3M	63.1M	67.3M
2018	49.8M	51.7M	53.5M	55.4M
2017	0	0	0	48.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of SI-BONE Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 03, 2024	recupero anthony j	sold	-14,379	15.6298	-920	president, commercial ops
Apr 02, 2024	recupero anthony j	sold	-51,272	15.5041	-3,307	president, commercial ops
Apr 02, 2024	maheshwari anshul	sold	-37,473	15.4531	-2,425	chief financial officer
Mar 13, 2024	nishimura mika	sold	-40,550	16.22	-2,500	-
Mar 13, 2024	recupero anthony j	sold	-56,022	16.8237	-3,330	president, commercial ops
Feb 16, 2024	dunn jeffrey w	sold	-87,172	20.955	-4,160	-
Feb 16, 2024	francis laura	sold	-808,591	20.955	-38,587	chief executive officer
Feb 16, 2024	recupero anthony j	sold	-163,910	20.955	-7,822	president, commercial ops
Feb 16, 2024	maheshwari anshul	sold	-153,726	20.955	-7,336	chief financial officer
Feb 02, 2024	dunn jeffrey w	sold	-6,799	20.2968	-335	-

Which funds bought or sold SIBN recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 05, 2024	CWM, LLC	added	4.2	-1,000	2,000	-%
Apr 05, 2024	GAMMA Investing LLC	new	-	557	557	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	reduced	-40.53	-3,284	4,681	-%
Mar 11, 2024	VANGUARD GROUP INC	added	4.82	1,759,370	50,792,300	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	396	8,347,330	10,484,600	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	added	13.93	46,415	415,035	-%
Feb 20, 2024	Quarry LP	new	-	27,665	27,665	-%
Feb 16, 2024	PRICE T ROWE ASSOCIATES INC /MD/	added	13.09	42,000	402,000	-%
Feb 15, 2024	Farther Finance Advisors, LLC	new	-	588	588	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	1,967,120	1,967,120	-%

Are Funds Buying or Selling SIBN?

Are funds buying SIBN calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SIBN

No. of Funds

Unveiling SI-BONE Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	first light asset management, llc	6.25%	2,532,227	SC 13G
Feb 14, 2024	orbimed advisors llc	5.3%	2,144,631	SC 13G/A
Feb 13, 2024	champlain investment partners, llc	2.96%	1,197,537	SC 13G/A
Feb 13, 2024	vanguard group inc	5.97%	2,419,831	SC 13G
Feb 09, 2024	brown advisory inc	10.3%	4,155,434	SC 13G/A
Jan 24, 2024	blackrock inc.	9.6%	3,907,197	SC 13G/A
Jan 22, 2024	integrated core strategies (us) llc	3.0%	1,203,538	SC 13G/A
May 11, 2023	integrated core strategies (us) llc	5.4%	2,081,497	SC 13G
Feb 14, 2023	first light asset management, llc	6.10%	2,104,337	SC 13G
Feb 14, 2023	orbimed advisors llc	9.3%	3,201,100	SC 13G/A

Recent SEC filings of SI-BONE Inc

View All Filings

Date Filed	Form Type	Document
Apr 04, 2024	4	Insider Trading
Apr 04, 2024	4	Insider Trading
Apr 03, 2024	144	Notice of Insider Sale Intent
Mar 14, 2024	144	Notice of Insider Sale Intent
Mar 14, 2024	4	Insider Trading
Mar 14, 2024	4	Insider Trading
Mar 13, 2024	144	Notice of Insider Sale Intent
Feb 27, 2024	10-K	Annual Report
Feb 27, 2024	S-8	Employee Benefits Plan
Feb 26, 2024	8-K	Current Report

Peers (Alternatives to SI-BONE Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	189.6B	40.1B	-5.40%	4.53%	33.12	4.73	-8.12%	-17.45%
BDX	66.7B	19.5B	-2.42%	-9.87%	53.13	3.42	4.02%	-22.04%
ALGN	22.9B	3.9B	-2.94%	-12.25%	51.49	5.93	3.42%	23.09%
BAX	20.1B	14.8B	-4.93%	-7.94%	7.56	1.36	2.12%	209.17%
MID-CAP
HSIC	9.2B	12.3B	-4.49%	-14.03%	22	0.74	-2.44%	-22.68%
ATR	9.2B	3.5B	-1.69%	15.70%	32.17	2.62	4.97%	18.89%
BIO	8.5B	2.7B	-12.27%	-39.23%	-13.41	3.2	-4.68%	82.43%
XRAY	6.4B	4.0B	-6.21%	-24.72%	-47.49	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-0.75%	15.36%	-565.58	9.37	33.86%	89.83%
PDCO	2.3B	6.6B	-5.91%	-4.69%	11.86	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.61%	-18.37%	-1.88	0.4	7.73%	-1066.14%
ANIK	380.0M	166.7M	0.59%	-11.05%	-4.6	2.28	6.67%	-456.34%
ANGO	260.4M	324.0M	21.04%	-28.41%	-1.35	0.8	-3.19%	-337.41%
APYX	48.2M	52.3M	-22.35%	-53.67%	-2.57	0.92	17.61%	19.28%
AEMD	3.8M	3.7M	-16.76%	269.23%	-0.31	1.01	5.77%	8.23%

SI-BONE Inc News

Latest updates

SI-BONE Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	14.2%	38,859,000	34,014,000	33,305,000	32,708,000	31,953,000	26,432,000	25,585,000	22,439,000	25,230,000	22,286,000	22,194,000	20,442,000	22,144,000	20,373,000	14,049,000	16,821,000	19,811,000	16,182,000	16,317,000	14,991,000	15,624,000
Gross Profit	6.3%	28,676,000	26,973,000	26,987,000	26,784,000	26,864,000	22,264,000	22,120,000	19,456,000	21,855,000	19,808,000	19,819,000	18,242,000	19,869,000	17,795,000	11,932,000	14,889,000	17,765,000	14,552,000	14,729,000	13,465,000	14,242,000
Operating Expenses	8.0%	41,182,000	38,142,000	38,950,000	38,077,000	38,158,000	35,830,000	40,001,000	36,324,000	35,786,000	33,007,000	32,784,000	29,817,000	27,740,000	26,470,000	22,071,000	26,771,000	26,250,000	25,133,000	22,867,000	22,264,000	18,549,000
S&GA Expenses	9.1%	28,937,000	26,512,000	27,492,000	27,313,000	27,609,000	25,669,000	28,843,000	25,605,000	26,353,000	23,525,000	23,084,000	20,922,000	19,982,000	18,772,000	15,755,000	19,281,000	19,266,000	16,443,000	16,727,000	15,815,000	12,607,000
R&D Expenses	6.2%	4,162,000	3,919,000	3,656,000	3,291,000	3,480,000	3,089,000	3,478,000	3,580,000	3,049,000	3,288,000	3,149,000	2,955,000	2,426,000	2,778,000	2,165,000	2,090,000	1,776,000	1,874,000	1,946,000	1,683,000	1,501,000
EBITDA Margin	-	-	-	-	-	-	-	-	-	-	-0.41	-0.45	-0.47	-0.50	-0.44	-0.47	-0.47	-0.49	-0.19	-0.19	-0.20	-0.21
Interest Expenses	0.6%	889,500	884,000	850,000	838,000	881,000	755,000	622,000	561,000	568,000	2,658,000	1,075,000	1,064,000	1,085,000	1,102,000	2,683,000	1,231,000	1,243,000	1,243,000	1,233,000	1,230,000	1,282,000
EBT Margin	-	-	-	-	-	-	-	-	-	-	-0.50	-0.51	-0.57	-0.60	-0.54	-0.57	-0.56	-0.57	-0.28	-0.29	-0.30	-0.32
Net Income	-9.6%	-10,983,000	-10,022,000	-11,206,000	-11,125,000	-11,175,000	-14,158,000	-18,513,000	-17,410,000	-14,477,000	-15,872,000	-13,981,000	-12,242,000	-8,979,000	-9,474,000	-12,472,000	-12,772,000	-9,098,000	-11,306,000	-8,654,000	-9,345,000	-5,313,000
Net Income Margin	5.4%	-0.31	-0.33	-0.38	-0.47	-0.58	-0.65	-0.69	-0.67	-0.63	-0.59	-0.52	-0.56	-	-	-	-	-	-	-	-	-
Free Cashflow	2.8%	-3,390,000	-3,486,000	-6,304,000	-13,332,000	-8,435,000	-10,099,000	-16,842,000	-15,786,000	-14,489,000	-9,732,000	-10,366,000	-11,335,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-0.2%	230	231	234	149	158	158	166	177	191	194	207	216	223	154	159	168	117	121	127	132	139
Current Assets	0.2%	211	211	213	128	138	139	148	161	176	186	199	208	218	150	155	162	111	113	119	129	136
Cash Equivalents	-37.8%	33.00	53.00	111	23.00	21.00	26.00	24.00	27.00	63.00	60.00	48.00	37.00	54.00	56.00	66.00	68.00	10.00	13.00	11.00	13.00	25.00
Inventory	-9.3%	20.00	22.00	21.00	18.00	17.00	17.00	16.00	15.00	11.00	10.00	8.00	7.00	6.00	5.00	5.00	6.00	5.00	5.00	4.00	4.00	3.00
Net PPE	-3.0%	16.00	16.00	18.00	17.00	16.00	14.00	13.00	10.00	9.00	8.00	8.00	7.00	5.00	4.00	4.00	4.00	4.00	3.00	3.00	2.00	2.00
Liabilities	6.6%	61.00	57.00	56.00	55.00	59.00	55.00	55.00	54.00	56.00	50.00	53.00	54.00	54.00	52.00	51.00	52.00	54.00	52.00	49.00	49.00	48.00
Current Liabilities	21.1%	23.00	19.00	18.00	17.00	21.00	19.00	17.00	15.00	17.00	15.00	13.00	14.00	13.00	12.00	12.00	21.00	19.00	13.00	10.00	10.00	9.00
Long Term Debt	0.1%	36.00	36.00	36.00	36.00	35.00	34.00	35.00	35.00	35.00	35.00	40.00	40.00	39.00	39.00	39.00	31.00	35.00	39.00	39.00	39.00	39.00
LT Debt, Current	-	-	-	-	-	-	1.00	-	-	-	-	-	-	-	-	-	9.00	4.00	-	-	-	-
LT Debt, Non Current	0.1%	36.00	36.00	36.00	36.00	35.00	34.00	35.00	35.00	35.00	35.00	40.00	40.00	39.00	39.00	39.00	31.00	35.00	39.00	39.00	39.00	39.00
Shareholder's Equity	-2.4%	169	174	177	94.00	98.00	103	111	122	134	144	154	162	169	102	108	116	63.00	69.00	78.00	83.00	90.00
Retained Earnings	-2.8%	-400	-389	-379	-368	-357	-345	-331	-313	-295	-281	-265	-251	-239	-230	-220	-208	-195	-186	-175	-166	-157
Additional Paid-In Capital	1.2%	569	563	557	462	455	449	443	436	430	425	419	413	408	332	328	324	258	255	252	249	247
Shares Outstanding	0.8%	41.00	40.00	40.00	35.00	35.00	34.00	34.00	34.00	34.00	33.00	33.00	33.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	1,100	-	-	-	443	-	1,000	-	-	-	-	-	394	-	-	-	391	-	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-10.8%	-2,297	-2,073	-3,590	-10,753	-6,775	-6,527	-14,841	-13,512	-12,714	-9,309	-8,151	-9,359	-7,882	-5,552	-7,873	-9,355	-9,033	-7,120	-8,396	-7,078	-6,317
Share Based Compensation	0.2%	5,937	5,928	5,998	6,194	5,881	5,922	5,751	5,507	4,338	4,241	4,257	4,030	3,170	3,180	2,955	2,622	1,868	1,911	1,814	1,871	1,231
Cashflow From Investing	65.5%	-18,912	-54,870	2,281	11,703	89.00	8,727	10,977	-22,608	15,378	26,753	16,571	-7,122	-67,819	-5,157	6,721	3,339	5,575	7,725	5,744	-5,553	-97,048
Cashflow From Financing	455.3%	842	-237	89,123	1,205	693	106	1,229	169	1,015	-5,543	2,216	601	73,038	467	-256	63,152	1,252	573	1,538	125	114,523

SIBN Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 138,886	$ 106,409
Cost of goods sold	29,466	15,705
Gross profit	109,420	90,704
Operating expenses:
Sales and marketing	110,254	107,726
Research and development	15,028	13,627
General and administrative	31,069	28,960
Total operating expenses	156,351	150,313
Loss from operations	(46,931)	(59,609)
Interest and other income (expense), net:
Interest income	6,916	1,304
Interest expense	(3,462)	(2,819)
Other income (expense), net	141	(132)
Net loss	(43,336)	(61,256)
Other comprehensive income (loss):
Unrealized gain (loss) of marketable securities	166	(65)
Changes in foreign currency translation	(63)	(55)
Comprehensive loss	$ (43,233)	$ (61,376)
Net loss per share, basic (in dollars per share)	$ (1.13)	$ (1.79)
Net loss per share, diluted (in dollars per share)	$ (1.13)	$ (1.79)
Weighted-average number of common shares used to compute basic net loss per share (in shares)	38,427,419	34,201,824
Weighted-average number of common shares used to compute diluted net loss per share (in shares)	38,427,419	34,201,824

SIBN Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 33,271	$ 20,717
Short-term investments	132,748	76,573
Accounts receivable, net of allowance for credit losses of $1,118 and $400, respectively	21,953	20,674
Inventory	20,249	17,282
Prepaid expenses and other current assets	3,173	2,365
Total current assets	211,394	137,611
Property and equipment, net	16,000	15,564
Operating lease right-of-use assets	2,706	4,002
Other non-current assets	325	375
TOTAL ASSETS	230,425	157,552
CURRENT LIABILITIES
Accounts payable	4,588	6,279
Accrued liabilities and other	17,452	13,511
Operating lease liabilities, current portion	1,416	1,388
Total current liabilities	23,456	21,178
Long-term borrowings	36,065	35,171
Operating lease liabilities, net of current portion	1,511	2,871
Other long-term liabilities	18	30
TOTAL LIABILITIES	61,050	59,250
Commitments and contingencies (Note 6)
STOCKHOLDERS’ EQUITY
Preferred stock, $0.0001 par value; 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, $0.0001 par value; 100,000,000 shares authorized; 40,693,299 and 34,731,577 shares issued and outstanding, respectively	4	3
Additional paid-in capital	569,477	455,172
Accumulated other comprehensive income	335	232
Accumulated deficit	(400,441)	(357,105)
TOTAL STOCKHOLDERS’ EQUITY	169,375	98,302
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 230,425	$ 157,552

About SI-BONE Inc

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and distributors. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California.

CEO	Ms. Laura A. Francis MBA
WEBSITE	https://si-bone.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	357

SI-BONE Inc Frequently Asked Questions

What is the ticker symbol for SI-BONE Inc? What does SIBN stand for in stocks?

SIBN is the stock ticker symbol of SI-BONE Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SI-BONE Inc (SIBN)?

As of Tue Apr 16 2024, market cap of SI-BONE Inc is 629.93 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SIBN stock?

You can check SIBN's fair value in chart for subscribers.

What is the fair value of SIBN stock?

You can check SIBN's fair value in chart for subscribers. The fair value of SI-BONE Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of SI-BONE Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SIBN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is SI-BONE Inc a good stock to buy?

The fair value guage provides a quick view whether SIBN is over valued or under valued. Whether SI-BONE Inc is cheap or expensive depends on the assumptions which impact SI-BONE Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SIBN.

What is SI-BONE Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 16 2024, SIBN's PE ratio (Price to Earnings) is -14.54 and Price to Sales (PS) ratio is 4.54. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SIBN PE ratio will change depending on the future growth rate expectations of investors.